Migraine affects up to 25% of women of reproductive age. Suboptimally treated migraine during pregnancy can negatively affect both mother and fetus, but few data exist on the safety of many commonly used pharmacotherapies for migraine. This Review summarizes current evidence on the safety of the most common antimigraine drugs during pregnancy and breastfeeding, and provides treatment recommendations for clinical practice.
- Siri Amundsen
- Hedvig Nordeng
- Olav Spigset
